Astrazeneca plc - ADR
AZN
Market Cap$209.29B
Close$
Earnings Call Q3 2024
November 12, 2024 - AI Summary
Strong Financial Performance: AstraZeneca reported a 21% revenue growth in Q3 2024 and a 19% growth year-to-date, driven by robust global demand across all therapy areas. Core EPS increased by 27% in Q3 and 11% year-to-date, despite a challenging comparative period in 2023 which included $1.1 billion from one-time collaboration revenue.
Upgraded Guidance: The company has upgraded its full-year guidance, now expecting total revenue and core EPS to grow by high teens percentages at constant exchange rates, reflecting strong underlying business performance and positive momentum entering 2025.
U.S. Investment Strategy: AstraZeneca announced a $3.5 billion investment in U.S. manufacturing and R&D, underscoring the U.S. as a vital market for innovation and growth. There is a strategic focus on increasing revenue market share in the U.S. as part of the company's long-term ambitions.
Exclusive for Stockcircle Pro members
Sign up
$87.97
28.2% upside
Current Fair Value
28.2% upsideUndervalued by 28.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $209.29 Billion |
|---|---|
| Enterprise Value | $237.53 Billion |
| Dividend Yield | $1.475 (1.38309058230659%) |
| Earnings per Share | $1.92 |
| Beta | 0.18 |
| Outstanding Shares | 3,100,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 31.84 |
|---|---|
| PEG | 795.49 |
| Price to Sales | 4.29 |
| Price to Book Ratio | 5.28 |
| Enterprise Value to Revenue | 4.61 |
| Enterprise Value to EBIT | 24.54 |
| Enterprise Value to Net Income | 36 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.81 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About AstraZeneca Plc
CEO: Pascal Soriot AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...